Stem Cell Therapeutics Corp.: Traumatic Brain Injury (TBI) Clinical Study Gains IRB Approval at University of Calgary

CALGARY, ALBERTA–(Marketwire – Aug. 13, 2010) – Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) (“SCT” or the “Company”) wishes to announce the IRB (Institutional Review Board) at the University of Calgary/Foothills Hospital has approved the SCT-sponsored investigator-lead Phase IIa study entitled “A Phase IIa, Single Center, Open Label Study to Characterize the Safety of Human Chorionic …